Cargando…
Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report
Surgery is the preferred treatment for basal cell carcinoma (BCC), locally advanced or metastatic BCC, radiation therapy or systemic therapy can be considered. Programmed death receptor 1 (PD-1) inhibitors are rarely used to treat cutaneous BCC. In the present case, we found that tislelizumab, a PD-...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174383/ https://www.ncbi.nlm.nih.gov/pubmed/37171300 http://dx.doi.org/10.1097/MD.0000000000033788 |
_version_ | 1785040016886464512 |
---|---|
author | Wu, Ming-Jun Chen, Yu-Chun Cui, Xiao-Li Yang, Qian Xue, Qing-Liang |
author_facet | Wu, Ming-Jun Chen, Yu-Chun Cui, Xiao-Li Yang, Qian Xue, Qing-Liang |
author_sort | Wu, Ming-Jun |
collection | PubMed |
description | Surgery is the preferred treatment for basal cell carcinoma (BCC), locally advanced or metastatic BCC, radiation therapy or systemic therapy can be considered. Programmed death receptor 1 (PD-1) inhibitors are rarely used to treat cutaneous BCC. In the present case, we found that tislelizumab, a PD-1 immunosuppressant, had a positive effect on BCC. PATIENT CONCERNS: A 74-year-old male patient presented with a mass in the left back in October 2021, which was surgically removed and diagnosed as BCC. The patient was diagnosed with squamous lung cancer after presenting with a cough and coughing up a small amount of white, sticky sputum in December 2021. DIAGNOSIS: BCC and squamous lung cancer. INTERVENTIONS: Docetaxel + nedaplatin systemic chemotherapy combined with tislelizumab immunotherapy. OUTCOMES: Both BCC and squamous lung cancer were significantly reduced in size. CONCLUSION: After 2 cycles of immunotherapy with tislelizumab, the lung tumor shrank, the back mass disappeared, and the wound healed. |
format | Online Article Text |
id | pubmed-10174383 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-101743832023-05-12 Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report Wu, Ming-Jun Chen, Yu-Chun Cui, Xiao-Li Yang, Qian Xue, Qing-Liang Medicine (Baltimore) 4200 Surgery is the preferred treatment for basal cell carcinoma (BCC), locally advanced or metastatic BCC, radiation therapy or systemic therapy can be considered. Programmed death receptor 1 (PD-1) inhibitors are rarely used to treat cutaneous BCC. In the present case, we found that tislelizumab, a PD-1 immunosuppressant, had a positive effect on BCC. PATIENT CONCERNS: A 74-year-old male patient presented with a mass in the left back in October 2021, which was surgically removed and diagnosed as BCC. The patient was diagnosed with squamous lung cancer after presenting with a cough and coughing up a small amount of white, sticky sputum in December 2021. DIAGNOSIS: BCC and squamous lung cancer. INTERVENTIONS: Docetaxel + nedaplatin systemic chemotherapy combined with tislelizumab immunotherapy. OUTCOMES: Both BCC and squamous lung cancer were significantly reduced in size. CONCLUSION: After 2 cycles of immunotherapy with tislelizumab, the lung tumor shrank, the back mass disappeared, and the wound healed. Lippincott Williams & Wilkins 2023-05-12 /pmc/articles/PMC10174383/ /pubmed/37171300 http://dx.doi.org/10.1097/MD.0000000000033788 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 4200 Wu, Ming-Jun Chen, Yu-Chun Cui, Xiao-Li Yang, Qian Xue, Qing-Liang Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report |
title | Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report |
title_full | Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report |
title_fullStr | Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report |
title_full_unstemmed | Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report |
title_short | Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report |
title_sort | tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: a case report |
topic | 4200 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174383/ https://www.ncbi.nlm.nih.gov/pubmed/37171300 http://dx.doi.org/10.1097/MD.0000000000033788 |
work_keys_str_mv | AT wumingjun tislelizumabforsquamouslungcancercombinedwithbasalcellcarcinomaoftheskinacasereport AT chenyuchun tislelizumabforsquamouslungcancercombinedwithbasalcellcarcinomaoftheskinacasereport AT cuixiaoli tislelizumabforsquamouslungcancercombinedwithbasalcellcarcinomaoftheskinacasereport AT yangqian tislelizumabforsquamouslungcancercombinedwithbasalcellcarcinomaoftheskinacasereport AT xueqingliang tislelizumabforsquamouslungcancercombinedwithbasalcellcarcinomaoftheskinacasereport |